A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
Study terminated due to low enrollment and availability of alternative protocols.
Staffing disruptions leading to incomplete study enrollment prior to PI departure.
Recruitment was prematurely terminated by the DSMB due to concern of harm for future participants based on interim data favoring the placebo group, findings from the N3RO trial, and the very low probability of benefit from DHA supplementation
Accrual and drug manufacturing and supply were discontinued in 2025.
Zimmer Biomet is prioritizing specific products within its portfolio and has chosen not to extend the CE mark for the GTS stem under MDR requirements, leading to the premature termination of the GTS study in 2024.
Terminated due to a business decision by the acquiring company to discontinue the marketed product. The post-market surveillance registry was no longer feasible. Not related to safety concerns.
Sponsor's decision
Owing to the Covid-19 epidemics, suspension of inclusions on Monday 16 march 2020 for an undetermined period of time Terminated prematurely due to an excessive number of deaths
Limited staff availability
Population difficult to recruit; number of enrolled patients sufficient for analyses.
recruitment difficulties
20 approvals month-to-date.
| Sponsor | Drug | Approved |
|---|---|---|
| NOVITIUM PHARMA | FOSFOMYCIN TROMETHAMINE | 2026-08-12 |
| AUROBINDO PHARMA LTD | TRIAMCINOLONE ACETONIDE | 2026-08-11 |
| BOSTAL DRUG | VALSARTAN | 2026-08-11 |
| VIWIT PHARM | GADOTERATE MEGLUMINE | 2026-08-10 |
| AUROBINDO PHARMA | BRIVARACETAM | 2026-08-10 |
8.1% of the last year's EMA authorisations were conditional.
None authorised this period.
4 new · 0 resolved · 104 currently active.
| Newly reported shortage | Posted |
|---|---|
| Fulvestrant Injection | 2026-08-14 |
| Diclofenac Sodium Tablet, Delayed Release | 2026-08-13 |
| Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution | 2026-08-13 |
| Glyburide Tablet | 2026-08-10 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 75,658 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Cairo University | 4,795 |
| Assiut University | 4,753 |
| GlaxoSmithKline | 3,625 |
| National Cancer Institute (NCI) | 3,553 |
| Assistance Publique - Hôpitaux de Paris | 3,539 |
| AstraZeneca | 3,472 |
| Pfizer | 3,293 |
| Mayo Clinic | 3,231 |
| M.D. Anderson Cancer Center | 3,018 |
| Novartis Pharmaceuticals | 2,685 |
| National Taiwan University Hospital | 2,590 |
| Massachusetts General Hospital | 2,559 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,437 |
| Boehringer Ingelheim | 2,285 |
| University of California, San Francisco | 2,149 |
| Stanford University | 2,144 |
| Riphah International University | 2,143 |
| Merck Sharp & Dohme LLC | 2,139 |
| Hoffmann-La Roche | 2,082 |
| Eli Lilly and Company | 2,074 |
| Duke University | 2,045 |
| Memorial Sloan Kettering Cancer Center | 1,942 |
| Seoul National University Hospital | 1,887 |
| Ain Shams University | 1,880 |
| Hospices Civils de Lyon | 1,835 |
| Condition | Trials |
|---|---|
| breast cancer | 11,816 |
| obesity disorder | 9,583 |
| type 2 diabetes mellitus | 9,150 |
| chronic pain syndrome | 8,820 |
| cancer | 8,254 |
| HIV infectious disease | 8,218 |
| COVID-19 | 7,646 |
| non-small cell lung carcinoma | 6,385 |
| hypertensive disorder | 6,139 |
| diabetes mellitus | 6,132 |
| cerebrovascular disorder | 6,030 |
| colorectal cancer | 6,029 |
| coronary artery disorder | 5,955 |
| prostate cancer | 5,861 |
| depressive disorder | 5,843 |
| cardiovascular disorder | 5,608 |
| anxiety disorder | 4,920 |
| heart failure | 4,908 |
| injury | 4,497 |
| Parkinson disease | 4,440 |
| asthma | 4,425 |
| cognitive disorder | 4,195 |
| lung cancer | 4,062 |
| benign essential hypertension | 3,886 |
| neuralgia | 3,839 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,189 |
| paclitaxel | 5,570 |
| isoniazid | 5,343 |
| prednisolone | 5,285 |
| cyclophosphamide | 5,125 |
| ropivacaine | 4,864 |
| dexamethasone | 4,808 |
| bevacizumab | 4,622 |
| cisplatin | 4,480 |
| lidocaine | 3,626 |
| aspirin | 3,402 |
| gemcitabine | 3,188 |
| bupivacaine | 3,128 |
| pembrolizumab | 2,994 |
| desoxycorticosterone acetate | 2,984 |
| metformin | 2,977 |
| sitagliptin and metformin hydrochloride | 2,963 |
| rituximab | 2,944 |
| meprednisone | 2,850 |
| dapagliflozin metformin hydrochloride | 2,788 |
| sitagliptin metformin hydrochloride | 2,773 |
| docetaxel | 2,764 |
| linagliptin and metformin hydrochloride | 2,760 |
| fluorouracil | 2,721 |
| alogliptin and metformin hydrochloride | 2,702 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,094 | 861 | 892 |
| AstraZeneca | 1,020 | 551 | 805 |
| Pfizer | 1,175 | 709 | 656 |
| Novartis Pharmaceuticals | 508 | 836 | 735 |
| Boehringer Ingelheim | 1,069 | 321 | 399 |
| Merck Sharp & Dohme LLC | 700 | 550 | 739 |
| Hoffmann-La Roche | 493 | 481 | 568 |
| Eli Lilly and Company | 828 | 536 | 548 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Valbenazine Tosylate | 2026-08-18 |
| Gallium Ga-68 Edotreotide | 2026-08-21 |
| Cobicistat | 2026-08-22 |
| Difelikefalin Acetate | 2026-08-23 |
| Sofosbuvir | 2026-08-28 |
| Ledipasvir; Sofosbuvir | 2026-08-28 |
| Citalopram Hydrobromide | 2026-09-16 |
| Phentolamine Mesylate | 2026-09-25 |
| Miglustat | 2026-09-28 |
| Atogepant | 2026-09-28 |
| Technetium Tc-99m Labeled Carbon | 2026-09-29 |
| Patiromer Sorbitex Calcium | 2026-10-02 |
| Risdiplam | 2026-10-03 |
| Dexamethasone | 2026-10-03 |
| Afamelanotide | 2026-10-08 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.